Misericordia Basora1, Arturo Pereira2, Miquel Coca1, Montse Tió1, Lluís Lozano3. 1. Department of Anaesthesiology, Hospital Clinic Barcelona, Barcelona, Spain. 2. Department of Haemotherapy and Haemostasis, Hospital Clinic Barcelona, Barcelona, Spain. 3. Department of Orthopaedic Surgery, Hospital Clinic Barcelona, Barcelona, Spain.
Abstract
BACKGROUND: An analytic-decision model was built to estimate the cost-effectiveness of using ferric carboxymaltose for pre-operative haemoglobin optimisation in patients with iron deficiency anaemia undergoing primary knee arthroplasty. MATERIALS AND METHODS: We simulated 20,000 patients who were randomly assigned to thehaemoglobin optimisation arm or the non-optimisation control arm in a strict 1:1 ratio. The main outcomes were cost per patient transfusion avoided and red blood cell units spared. The analyses were performed from the hospital perspective with length of stay as the time horizon. RESULTS: In the reference case scenario, pre-operative haemoglobin optimisation led to fewer patients being exposed to allogeneic red blood cell transfusion (2,212 vs 6,595 out of 10,000 patients) and a relevant decrease in the number of red blood cell units transfused (4.342 vs 13.336). The costs of avoiding one patient transfusion and sparing one red blood cell unit were € 831 and € 405, respectively. Increased costs in the optimisation arm were mostly associated with the outpatient day hospital visit (54%) and ferric carboxymaltose treatment (40%). DISCUSSION: In primary knee arthroplasty, pre-operative haemoglobin optimisation with intravenous ferric carboxymaltose is less expensive than other reported patient blood management modalities and must be considered in patients with iron deficiency anaemia.
RCT Entities:
BACKGROUND: An analytic-decision model was built to estimate the cost-effectiveness of using ferric carboxymaltose for pre-operative haemoglobin optimisation in patients with iron deficiency anaemia undergoing primary knee arthroplasty. MATERIALS AND METHODS: We simulated 20,000 patients who were randomly assigned to the haemoglobin optimisation arm or the non-optimisation control arm in a strict 1:1 ratio. The main outcomes were cost per patient transfusion avoided and red blood cell units spared. The analyses were performed from the hospital perspective with length of stay as the time horizon. RESULTS: In the reference case scenario, pre-operative haemoglobin optimisation led to fewer patients being exposed to allogeneic red blood cell transfusion (2,212 vs 6,595 out of 10,000 patients) and a relevant decrease in the number of red blood cell units transfused (4.342 vs 13.336). The costs of avoiding one patient transfusion and sparing one red blood cell unit were € 831 and € 405, respectively. Increased costs in the optimisation arm were mostly associated with the outpatient day hospital visit (54%) and ferric carboxymaltose treatment (40%). DISCUSSION: In primary knee arthroplasty, pre-operative haemoglobin optimisation with intravenous ferric carboxymaltose is less expensive than other reported patient blood management modalities and must be considered in patients with iron deficiency anaemia.
Authors: Michael F Leahy; Axel Hofmann; Simon Towler; Kevin M Trentino; Sally A Burrows; Stuart G Swain; Jeffrey Hamdorf; Trudi Gallagher; Audrey Koay; Gary C Geelhoed; Shannon L Farmer Journal: Transfusion Date: 2017-02-02 Impact factor: 3.157
Authors: Oliver Ng; Barrie D Keeler; Amitabh Mishra; Alastair Simpson; Keith Neal; Matthew J Brookes; Austin G Acheson Journal: Cochrane Database Syst Rev Date: 2015-12-22
Authors: Cynthia So-Osman; Rob G H H Nelissen; Ankie W M M Koopman-van Gemert; Ewoud Kluyver; Ruud G Pöll; Ron Onstenk; Joost A Van Hilten; Thekla M Jansen-Werkhoven; Wilbert B van den Hout; Ronald Brand; Anneke Brand Journal: Anesthesiology Date: 2014-04 Impact factor: 7.892
Authors: Cynthia So-Osman; Rob G H H Nelissen; Ankie W M M Koopman-van Gemert; Ewoud Kluyver; Ruud G Pöll; Ron Onstenk; Joost A Van Hilten; Thekla M Jansen-Werkhoven; Wilbert B van den Hout; Ronald Brand; Anneke Brand Journal: Anesthesiology Date: 2014-04 Impact factor: 7.892
Authors: Toby Richards; Ben Clevenger; Jane Keidan; Tim Collier; Andrew A Klein; Stefan D Anker; John D Kelly Journal: Trials Date: 2015-07-24 Impact factor: 2.279
Authors: Terry M Zwiep; Richard W D Gilbert; Husein Moloo; Donna Touchie; Guillaume Martel; Tom Wallace; Kimberly A Bertens Journal: Patient Saf Surg Date: 2020-04-24